Rita Nanda to Immunotherapy
This is a "connection" page, showing publications Rita Nanda has written about Immunotherapy.
Connection Strength
1.697
-
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC). Clin Breast Cancer. 2024 Jun; 24(4):263-270.
Score: 0.551
-
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer. Sci Transl Med. 2026 Apr 22; 18(846):eaec2358.
Score: 0.160
-
Triple negative breast cancer: what clinical progress have we seen in the last 5?years? Expert Opin Investig Drugs. 2026 Mar; 35(3):223-238.
Score: 0.157
-
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.
Score: 0.150
-
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 02 03; 8(2):e2460243.
Score: 0.147
-
Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
Score: 0.123
-
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs. 2022 Jun; 31(6):531-548.
Score: 0.117
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 08; 9(8).
Score: 0.115
-
Immune Checkpoint Blockade for Breast Cancer. Cancer Treat Res. 2018; 173:155-165.
Score: 0.090
-
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med. 2017 10 11; 15(1):205.
Score: 0.088